Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

Abstract Rhabdomyosarcomas (RMS) are mesenchyme‐derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high‐risk patients. Discovery of new therapies would benefit from additional preclinical models. Here, we describe the gener...

Full description

Bibliographic Details
Main Authors: Michael T Meister, Marian J A Groot Koerkamp, Terezinha de Souza, Willemijn B Breunis, Ewa Frazer‐Mendelewska, Mariël Brok, Jeff DeMartino, Freek Manders, Camilla Calandrini, Hinri H D Kerstens, Alex Janse, M Emmy M Dolman, Selma Eising, Karin P S Langenberg, Marc van Tuil, Rutger R G Knops, Sheila Terwisscha van Scheltinga, Laura S Hiemcke‐Jiwa, Uta Flucke, Johannes H M Merks, Max M van Noesel, Bastiaan B J Tops, Jayne Y Hehir‐Kwa, Patrick Kemmeren, Jan J Molenaar, Marc van de Wetering, Ruben van Boxtel, Jarno Drost, Frank C P Holstege
Format: Article
Language:English
Published: Springer Nature 2022-08-01
Series:EMBO Molecular Medicine
Subjects:
rhabdomyosarcoma
mesenchymal
tumoroid
drug screening
CRISPR/Cas9
Online Access:https://doi.org/10.15252/emmm.202216001

Similar Items

Similar Items